CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 87,431	$ 57,421
Prepaid expenses and other current assets	4,489	5,156
Research and development incentives receivables	2,020	1,183
Total current assets	93,940	63,760
Property and equipment, net	338	405
Operating lease right of use assets, net	985	1,245
Intangible assets, net	866	1,089
Total assets	96,129	66,499
Current liabilities:
Accounts payable	2,700	2,346
Accrued expenses	3,721	5,467
Convertible loan notes - current	4,931	0
Operating lease liabilities - current	679	652
Other current liabilities	3,435	1,021
Total current liabilities	15,466	9,486
Convertible loan notes - non current	0	4,394
Warrant liabilities - non current	925	412
Operating lease liabilities- non current	552	906
Other non-current liabilities	536	764
Total liabilities	17,479	15,962
Commitments and contingencies (Note 16)
Shareholders' Equity
Ordinary shares, par value 0.003 per share; 768,821,274 shares issued at June 30, 2024 (December 31, 2023: 701,217,089).	3,032	2,775
Treasury shares	0	(1,230)
Additional paid-in capital	534,732	486,107
Accumulated deficit	(440,836)	(419,630)
Accumulated other comprehensive loss	(18,278)	(17,485)
Total shareholders' equity	78,650	50,537
Total liabilities and shareholders' equity	$ 96,129	$ 66,499

Current portion of research and development incentives receivables.

No definition available.

Name:	mreo_ResearchAndDevelopmentIncentivesReceivablesCurrent
Namespace Prefix:	mreo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).